文献速递胃肠动力与功能性疾病

胃电刺激对难治性呕吐经济负担的影响:法国全国多中心研究

Impact of Gastric Electrical Stimulation on Economic Burden of Refractory Vomiting: A French Nationwide Multicentre Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-11-13

这项法国全国多中心前瞻性研究评估了Enterra胃电刺激治疗难治性恶心呕吐的疗效、安全性和经济影响。142例患者临床数据显示胃肠道生活质量指数提高12.1分,每月呕吐少于1次的比例增加25.5%;96例经济数据显示人均年医疗费用从8873美元降至5525美元,每年节省3348美元。

要点

  • Enterra胃电刺激可改善难治性恶心呕吐患者的生活质量并减少呕吐频率
  • 该治疗使人均年医疗总费用从8873美元降至5525美元,净节省3348美元
  • 糖尿病患者的经济节省(每年4096美元)高于非糖尿病患者(每年2900美元)

核心结论

  • Enterra胃电刺激治疗对难治性恶心呕吐患者有效、安全且具有成本效益。

研究设计与样本

  • 法国全国多中心前瞻性研究,纳入植入Enterra设备的药物难治性恶心和/或呕吐患者并随访两年。
  • 142例患者有完整临床数据(60例糖尿病,82例非糖尿病),96例患者有医学经济学数据(36例糖尿病,60例非糖尿病)。

主要发现

  • 植入后24个月,胃肠道生活质量指数(GIQLI)评分平均提高12.1±25.0分(p<.001)。
  • 非糖尿病患者GIQLI改善(+15.8±25.0分,p<.001)优于糖尿病患者(+7.3±24.5分,p=.027)。
  • 每月呕吐少于1次的患者比例增加25.5%(p<.001)。
  • 住院、误工和交通是主要费用来源;Enterra治疗使人均年整体医疗费用从8873美元降至5525美元(p=.001)。
  • 糖尿病患者每年节省4096美元,非糖尿病患者每年节省2900美元。

临床怎么用

  • 对于药物难治性恶心呕吐患者,可考虑Enterra胃电刺激作为有效、安全且能降低医疗费用的治疗选择。
  • 非糖尿病患者在生活质量改善方面可能获益更明显,而糖尿病患者在经济费用节省方面可能获益更大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Medico-economic data of patients suffering from chronic nausea and vomiting are lacking. In these patients, gastric electrical stimulation (GES) is an effective, but costly treatment. The aim of this study was to assess the efficacy, safety and medico-economic impact of Enterra therapy in patients with chronic medically refractory nausea and vomiting. METHODS: Data were collected prospectively from patients with medically refractory nausea and/or vomiting, implanted with an Enterra device and followed for two years. Gastrointestinal quality of life index (GIQLI) score, vomiting frequency, nutritional status and safety were evaluated. Direct and indirect expenditure data were prospectively collected in diaries. RESULTS: Complete clinical data were available for142 patients (60 diabetic, 82 non-diabetic) and medico-economic data were available for 96 patients (36 diabetic, 60 non-diabetic), 24 months after implantation. GIQLI score increased by 12.1 ± 25.0 points (p < .001), with a more significant improvement in non-diabetic than in diabetic patients (+15.8 ± 25.0 points, p < .001 versus 7.3 ± 24.5 points, p = .027, respectively). The proportion of patients vomiting less than once per month increased by 25.5% (p < .001). Hospitalisations, time off work and transport were the main sources of costs. Enterra therapy decreased mean overall healthcare costs from 8873 US$ to 5525 US$ /patient/year (p = .001), representing a saving of 3348 US$ per patient and per year. Savings were greater for diabetic patients (4096 US$ /patient/year) than for non-diabetic patients (2900 US$ /patient/year). CONCLUSIONS: Enterra therapy is an effective, safe and cost-effective option for patients with refractory nausea and vomiting. CLINICALTRIALS: gov Identifier: NCT00903799.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Gourcerol G, Coffin B, Bonaz B, et al. Impact of Gastric Electrical Stimulation on Economic Burden of Refractory Vomiting: A French Nationwide Multicentre Study. Clin Gastroenterol Hepatol. 2020. PMID: 33189854. doi:10.1016/j.cgh.2020.11.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。